Changing profiles of cancer burden worldwide and in China: a secondary analysis of the global cancer statistics 2020

Wei Cao, Hong-Da Chen, Yi-Wen Yu, Ni Li, Wan-Qing Chen, Wei Cao, Hong-Da Chen, Yi-Wen Yu, Ni Li, Wan-Qing Chen

Abstract

Background: Cancer is one of the leading causes of death globally, but its burden is not uniform. GLOBOCAN 2020 has newly updated the estimates of cancer burden. This study summarizes the most recent changing profiles of cancer burden worldwide and in China and compares the cancer data of China with those of other regions.

Methods: We conducted a descriptive secondary analysis of the GLOBOCAN 2020 data. To depict the changing global profile of the leading cancer types in 2020 compared with 2018, we extracted the numbers of cases and deaths in 2018 from GLOBOCAN 2018. We also obtained cancer incidence and mortality from the 2015 National Cancer Registry Report in China when sorting the leading cancer types by new cases and deaths. For the leading cancer types according to sex in China, we summarized the estimated numbers of incidence and mortality, and calculated China's percentage of the global new cases and deaths.

Results: Breast cancer displaced lung cancer to become the most leading diagnosed cancer worldwide in 2020. Lung, liver, stomach, breast, and colon cancers were the top five leading causes of cancer-related death, among which liver cancer changed from the third-highest cancer mortality in 2018 to the second-highest in 2020. China accounted for 24% of newly diagnosed cases and 30% of the cancer-related deaths worldwide in 2020. Among the 185 countries included in the database, China's age-standardized incidence rate (204.8 per 100,000) ranked 65th and the age-standardized mortality rate (129.4 per 100,000) ranked 13th. The two rates were above the global average. Lung cancer remained the most common cancer type and the leading cause of cancer death in China. However, breast cancer became the most frequent cancer type among women if the incidence was stratified by sex. Incidences of colorectal cancer and breast cancer increased rapidly. The leading causes of cancer death varied minimally in ranking from 2015 to 2020 in China. Gastrointestinal cancers, including stomach, colorectal, liver, and esophageal cancers, contributed to a massive burden of cancer for both sexes.

Conclusions: The burden of breast cancer is increasing globally. China is undergoing cancer transition with an increasing burden of lung cancer, gastrointestinal cancer, and breast cancers. The mortality rate of cancer in China is high. Comprehensive strategies are urgently needed to target China's changing profiles of the cancer burden.

Conflict of interest statement

None.

Copyright © 2021 The Chinese Medical Association, produced by Wolters Kluwer, Inc. under the CC-BY-NC-ND license.

Figures

Figure 1
Figure 1
Rank changes in the most common cancer types (A) and leading causes of cancer-related death (B) based on the estimation of new cases and deaths worldwide, 2018–2020. Blue represents no change, red represents rank increase, and green represents rank decrease.
Figure 2
Figure 2
Estimated number of new cases (A) and cancer-related deaths (B) from of the common cancer types in 2015 and 2020, China. CNS: Central nervous system.
Figure 3
Figure 3
Estimated increase in the number of new cases (A) and deaths (B) of all cancer types on the basis of 2020 worldwide and in China.

References

    1. Vineis P, Wild CP. Global cancer patterns: causes and prevention. Lancet 2014; 383:549–557. doi: 10.1016/S0140-6736(13)62224-2.
    1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2018; 68:394–424. doi: 10.3322/caac.21492.
    1. Zhang S, Sun K, Zheng R, Zeng H, Wang S, Chen R, et al. . Cancer incidence and mortality in China, 2015. J Natl Cancer Center 2020; In press. doi: 10.1016/j.jncc.2020.12.001.
    1. Brustugun OT, Møller B, Helland Å. Years of life lost as a measure of cancer burden on a national level. Br J Cancer 2014; 111:1014–1020. doi: 10.1038/bjc.2014.364.
    1. Maule M, Merletti F. Cancer transition and priorities for cancer control. Lancet Oncol 2012; 13:745–746. doi: 10.1016/S1470-2045(12)70268-1.
    1. Sun D, Cao M, Li H, He S, Chen W. Cancer burden and trends in China: a review and comparison with Japan and South Korea. Chin J Cancer Res 2020; 32:129–139. doi: 10.21147/j.issn.1000-9604.2020.02.01.
    1. Feng RM, Zong YN, Cao SM, Xu RH. Current cancer situation in China: good or bad news from the 2018 Global Cancer Statistics? Cancer Commun 2019; 39:1–12. doi: 10.1186/s40880-019-0368-6.
    1. Cao M, Chen W. Cancer burden and control in China. Ann Cancer Epidemiol 2019; 3:4.doi: 10.21037/ace.2019.08.02.
    1. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. . Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2021; doi: 10.3322/caac.21660. Online ahead of print.
    1. Ferlay J, Colombet M, Soerjomataram I, Parkin DM, Piñeros M, Znaor A, et al. GLOBOCAN 2020 annexes; 2021. Available from: . [Last accessed on 2021 February 9].
    1. International Agency for Research on Cancer (IARC); 2021. Available from: . [Last accessed on 2021 February 9].
    1. International Agency for Research on Cancer (IARC); 2020. Available from: . [Last accessed on 2021 February 9].
    1. Huang Z, Hankinson SE, Colditz GA, Stampfer MJ, Hunter DJ, Manson JE, et al. . Dual effects of weight and weight gain on breast cancer risk. JAMA 1997; 278:1407–1411. doi: 10.1001/jama.1997.03550170037029.
    1. Pfeiffer RM, Webb-Vargas Y, Wheeler W, Gail MH. Proportion of US trends in breast cancer incidence attributable to long-term changes in risk factor distributions. Cancer Epidemiol Biomarkers Prev 2018; 27:1214–1222. doi: 10.1158/1055-9965.EPI-18-0098.
    1. DeSantis CE, Bray F, Ferlay J, Lortet-Tieulent J, Anderson BO, Jemal A. International variation in female breast cancer incidence and mortality rates. Cancer Epidemiol Biomarkers Prev 2015; 24:1495–1506. doi: 10.1158/1055-9965.EPI-15-0535.
    1. Akinyemiju T, Abera S, Ahmed M, Alam N, Alemayohu MA, et al. . Global Burden of Disease Liver Cancer Collaboration. The burden of primary liver cancer and underlying etiologies from 1990 to 2015 at the global, regional, and national level: results from the global burden of disease study 2015. JAMA Oncol 2017; 3:1683–1691. doi: 10.1001/jamaoncol.2017.3055.
    1. Ma J, Siegel RL, Islami F, Jemal A. Temporal trends in liver cancer mortality by educational attainment in the United States, 2000-2015. Cancer 2019; 125:2089–2098. doi: 10.1002/cncr.32023.
    1. Tapper EB, Parikh ND. Mortality due to cirrhosis and liver cancer in the United States, 1999-2016: observational study. BMJ 2018; 362:k2817.doi: 10.1136/bmj.k2817.
    1. Cao M, Chen W. Epidemiology of lung cancer in China. Thorac Cancer 2019; 10:3–7. doi: 10.1111/1759-7714.12916.
    1. Li H, Zeng H, Zheng R, Zou X, Cao M, Sun D, et al. . Association of cancer awareness levels with the risk of cancer in rural China: a population-based cohort study. Cancer 2020; 126:4563–4571. doi: 10.1002/cncr.33029.
    1. Li H, Zheng RS, Zhang SW, Zeng HM, Sun KX, Xia CF, et al. . Incidence and mortality of female breast cancer in China, 2014 (in Chinese). Chin J Oncol 2018; 40:166–171. doi: 10.3760/cma.j.issn.0253-3766.2018.03.002.
    1. Chen W, Xia C, Zheng R, Zhou M, Lin C, Zeng H, et al. . Disparities by province, age, and sex in site-specific cancer burden attributable to 23 potentially modifiable risk factors in China: a comparative risk assessment. Lancet Global Health 2019; 7:e257–e269. doi: 10.1016/S2214-109X(18)30488-1.
    1. Chen W, Li N, Shi J, Chen H, Li J. Progress of cancer screening program in urban China (in Chinese). China Cancer 2019; 28:23–25. doi: 10.11735/j.issn.1004-0242.2019.01.A003.
    1. Shi JF, Dai M. Health economic evaluation of cancer screening in China (in Chinese). Chin J Prev Med 2017; 51:107–111. doi: 10.3760/cma.j.issn.0253-9624.2017.02.002.
    1. Islami F, Chen W, Yu XQ, Lortet-Tieulent J, Zheng R, Flanders WD, et al. . Cancer deaths and cases attributable to lifestyle factors and infections in China, 2013. Ann Oncol 2017; 28:2567–2574. doi: 10.1093/annonc/mdx342.
    1. Surveillance, Epidemiology, and End Results Program (SEER). What is a Cancer Registry? Available from: . [Last accessed on 2021 February 9].
    1. Bray F, Mery L, Piñeros M, Znaor A, Zanetti R, Ferlay J. Cancer incidence in five continents, Vol. XI Lyon, IARC. International Agency for Research on Cancer; 2017. Available from: . [Last accessed on 2021 February 9].
    1. Piñeros M, Abriata MG, de Vries E, Barrios E, Bravo LE, Cueva P, et al. . Progress, challenges and ways forward supporting cancer surveillance in Latin America. Int J Cancer 2020; doi: 10.1002/ijc.33407. Online ahead of print.
    1. Chen W, Zheng R, Baade P, Zhang S, Zeng H, Bray F, et al. . Cancer statistics in China. CA Cancer J Clin 2016; 66:115–132. doi: 10.3322/caac.21338.
    1. National Cancer Registry Coverage. China: National Cancer Center, 2020. Available from: . [Last accessed on 2021 February 9].
    1. Siegel R, Miller K, Fuchs H, Jemal A. Cancer statistics. CA Cancer J Clin 2021; 71:7–33. doi: 10.3322/caac.21654.

Source: PubMed

Спонсоры и соавторы

Заболевания

Медикаментозные вмешательства

Подписаться